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Abstract. The third EU COST Action CM1103
“Structure-based drug design for diagnosis and
treatment of neurological diseases: dissecting and
modulating complex function in the monoaminergic
systems of the brain” Annual Conference entitled “Neu-
ropathology and Neuropharmacology of Monoaminergic
Systems” was hosted by the University of Bordeaux,
France on 8-10 October 2014. The conference, or-
ganized by Prof. De Deurwaerde´re, was supported
by COST (European Cooperation in Science and
Technology) and LABEX (LABEX Brain, University of
Bordeaux). The program took the form of a three-day
meeting, comprising a series of French and international
invited talks and breakout sessions designed to identify
key gaps in current knowledge and potential future
research questions. The aims of this Conference were
two-fold: 1. To identify the current state-of-the-art
in the understanding of the pathological mechanisms
that contribute to different neuropsychiatric disorders,
and to what extent, monoamines a multi-target drugs
and/or other interventions might prevent these changes.
2. To identify specific areas of research where informa-
tion is sparse but which are likely to yield data that will
impact on future strategies to treat neurodegenerative
disorders.
Meeting report
COST Action CM1103 (http://www.cost.eu/
domains actions/cmst/Actions/CM1103) Structure-
Based Drug Design For Diagnosis And Treatment
of Neurological Diseases: Dissecting and Modulating
Complex Function in the Monoaminergic Systems of the
Brain was established to stimulate an interdisciplinary
approach to the task of understanding the molecular ba-
sis of neurological and psychiatric disorders. Medicinal
chemistry now has many computational tools to aid in
the design of novel drugs targeting either one or several
proteins. Biological insights are essential to evaluate
the efficacy of these novel drugs and to propose also
new targets and approaches. Commonalities amongst
the brain monoamine neurotransmitters, dopamine
(DA), noradrenaline (NA), adrenaline (A) serotonin
(5-HT) or histamine, are evident as these systems of
neurotransmission are all involved in the pathophys-
iology of all major neuropsychiatric disorders and
brain affections, such as mood disorders, schizophrenia,
autism-spectrum disorders, Parkinson’s disease (PD),
Alzheimer disease, epilepsy, ischemia and dementias.
Indeed, the efficacy of numerous medicines against the
above-mentioned pathologies has been related at least
in part to an action of these chemical drugs on the
monoaminergic systems. The collaborative work in the
action is a permanent interaction between bottom-up
and top-down analyses towards understanding the neu-
ropathology and neuropharmacology of monoaminergic
systems. The extended abstracts in these Proceedings
are a selection from the contributions to the third
annual meeting, held in Bordeaux, of groups actively
working towards these goals.
Chemical developments come from existing molecules
and their modification either via classical or new ways
of synthesis, and computational modeling. Reported
at this conference are compounds for single targets
such as acetylcholinesterase or aldo-ketoreductase by
Magdalena Majekova (Slovak Academy of Sciences,
Bratislava), or families of compounds such as benzothia-
zoles by Kamil Musilek (Kadir Has University, Istanbul)
or quinolines by Jose´ Marco-Contelles (Consejo Supe-
rior de Investigaciones Cient´ıficas, Madrid) synthesized
and studied with the goal of treating Alzheimer disease,
Parkinson’s disease or stroke by Mercedes Unzeta (Uni-
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versitat Autonoma de Barcelona). A series of multi-
target compounds has been also designed with action
on specific pairs (or multiples) of targets. Ligands care-
fully designed to bind to multiple targets are another
accepted strategy in tackling the complex neurodegen-
erative diseases (Cavalli et al., 2008; Geldenhuys and
der Schyf, 2013) but producing the best combinations
to explore phenotypic results is not a trivial task (Prati
et al., 2014). With large numbers of compounds tested
and published in databases, one starting point comes
from data-mining existing knowledge. Theoretical pre-
diction of pharmaceutical targets for new compounds is
possible using a probabilistic method to build a model
of any compound from the ChEMBL dataset. Then,
using the circular fingerprint descriptors, a cheminfor-
matic method, developed to explore known off-target
interactions of known compounds, was applied to iden-
tify which of the new compounds that should bind to the
desired targets. This and confirmation of the predicted
efficacies are included in this topic.
Reuptake transporters are targets to modulate amine
levels in the synaptic cleft, but, unfortunately, crystal
structures are not available yet. Nonetheless, homology
models of the transporters in conjunction with muta-
tional studies are beginning to define the molecular de-
terminants of binding to these proteins. Structure-based
drug design together with good pharmacological data
provides the basis for designs combining the features
needed for each target into one molecule. These molec-
ular determinants predict quite nicely the behaviour
of some compounds (amphetamine, tyramine, cocaine,
DA, 5-HT; Yelekci and Connaly, this conference) toward
the dopamine transporter in models in vitro or in vivo
(Navailles and De Deurwaerde`re, 2011).
Drug design and computational studies are rendered
easier by the crystal structures that identify the in-
teraction of the protein with a ligand. Structures for
the enzymes that degrade the monoamine neurotrans-
mitters (MAO and COMT) are available for computa-
tional exploration of molecular determinants of bind-
ing. Inhibition of monoamine oxidases (MAO A and
MAO B) by several irreversible inhibitors and a few
new, well-tolerated, reversible inhibitors used over the
last 30 years, results in increased levels of brain amines
(Youdim and Bakhle, 2006). Docking and molecular dy-
namic studies of the inhibitor in the active site are now
standard tools for medicinal chemists aiming to improve
inhibitor binding or decide which part of a molecule may
be changed without loss of affinity (Samadi et al., 2012).
Using structure-based techniques, complete theoretical
searches for new lead compounds are also possible (Vilar
et al., 2012). Finally, using these models, it is possible
to address the selectivity of series of new compounds to-
ward MAO. More recently, the crystal structure of gluta-
matergic AMPA receptors has been obtained, leading to
conceive new series of compounds targeting the GluR1
subunit of the AMPA receptor hopefully as efficiently
as antinociceptive compounds as described by Stefania
Butini (University of Siena).
Pharmacological evaluation is still a necessary step
to determine the accurate efficacy of compounds and to
evaluate the selectivity towards other targets. Several
MAOI are not selective for MAO and display good affini-
ties for other targets such as lysine-specific demethylases
or cytochrome P450 (Binda et al., 2010); Massimo Val-
oti (University of Siena); Thomas Malcomson (Univer-
sity of St Andrews). Lysine-specific demethylases are in-
volved in epigenetic, cytochrome oxidase are involved in
the metabolism of xenobiotics. These other targets to-
gether may participate in the behavioural effects of these
compounds in animal models and in humans. Indeed,
as detailed by Marco Bortolato (University of Kansas)
gene deletion of MAOA gives surprising results com-
pared to pharmacological compounds (Finberg, 2014).
Apart from the longitudinal and developmental dimen-
sions inherent to gene deletion, Keith Tipton (Trinity
College, Dublin) showed that the differences suggest
that the biological effects of MAOI do not only result
from their interaction with MAO (Finberg, 2014).
Neuropharmacological explorations of the mechanism
of action of current drugs are a big challenge in neuro-
biology in order to identify the targets, ameliorate the
phenotype, and limit the side effects. Even if these drugs
are currently used in clinic, their mechanism of action
is often misunderstood, not only for MAOI. L-DOPA
is the gold standard medication in Parkinson’s disease
but the numerous motor and non-motor side effects oc-
curring after years of treatment lead to conceive other
therapeutic strategies and to focus on its mechanism of
action (Meissner et al., 2011). Numerous strategies are
developed to find new chemical compounds able to stim-
ulate the DA D2 and D3 receptors, the primary mech-
anism thought to underline the efficacy of L-DOPA.
The chemical development of new compounds unmasks
new pharmacological concepts and the development of
compounds will integrate these new concepts such as
biased signaling or heterodimerization of receptors, as
detailed by Holger Stark (Heinrich Heine University).
Abdelhamid Benazzouz (Universite´ de Bordeaux) em-
phasized the importance of the deep brain stimulation
that also permits to highlight unpredicted targets such
as D5 receptors, 5-HT2C receptors in the control of
DA neurons (De Deurwaerde`re et al., 2013) or to high-
light the involvement of 5-HT and NA neurons in the
control of dopamine-mediated function (Di Matteo et
al., 2008; Navailles, Di Giovanni and De Deurwaerde`re,
2014; Navailles, Milan et al., 2014). Finally, Philippe De
Deurwaerde`re (Universite´ de Bordeaux) presented evi-
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Figure 1: Some members of EU COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological
diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” at the Annual Conference
“Neuropathology and Neuropharmacology of Monoaminergic Systems” hosted by the University of Bordeaux, France on 8-10
October 2014.
dence that the chronic use of L-DOPA could affect the
activity of MAO enzymes in vivo showing that the dif-
ferent topics developed in the action are interconnected.
Understanding the interactions of neurotransmission
systems is an important step for the optimization of
therapeutic strategies. The plurality of targets that
potentially bind antipsychotics or antiparkinsonian, an-
tidepressant drugs favours the need to develop multi-
target compounds. Because neurobiological systems of
neurotransmitters establish close relationships (Chesse-
let, 1984), it is likely that a pharmacological action to-
ward one system will more or less directly affect the
other one. This is highlighted perhaps by famous asso-
ciations and links between some neurotransmitter sys-
tems such as the 5-HT/DA interaction (Di Giovanni et
al., 2008; Di Matteo et al., 2008), the glutamate/DA
interaction (M. Carlsson and A. Carlsson, 1990), the
5-HT/GABA interaction (Soubrie´, 2010) and so one.
The role of monoamines still remains unresolved even
in pathologies such as depression or anxiety where the
connection between monoamines and the diseases has
been known for years. In epilepsy, although monoamines
were thought to control the excitability of hippocampal
cells via a lowering influence on depolarizing current,
Giuseppe Di Giovanni (University of Malta and Cardiff
University), found that 5-HT2C receptors do not modify
the electrophysiological responses in the model of maxi-
mal dentate activation (MDA) of temporal lobe epilepsy
(TLE) while they undergo to a cellular redistribution in
the hippocampus of epileptic rats (Orban et al., 2014).
Di Giovanni also showed that in the pilocarpine-model of
TLE, the activation of the 5-HT2C receptors surprisingly
induce a powerful antiepileptic effect, probably medi-
ated by interacting with GABA and glutamate. These
findings highlight a strong model-dependence of the 5-
HT2C receptor effects which is especially true for TLE
epilepsy.
Moreover, the physiopathology of numerous patholo-
gies is still misunderstood. Nela Pivac (Rudjer Boskovic
Institute, Zagreb) presented some data concerning the
post-traumatic stress disorder, a pathology that proba-
bly involves monoamines, but devoid of efficient treat-
ment.
A better understanding of the relationships of chem-
ical systems in the brain relies on the availability of
good chemical compounds for research and diagnosis
and good models to address the efficacy of compounds
and the physiopathology of brain diseases. These mod-
els are sometimes classical as those that have been de-
veloped in rodents to study numerous neuropsychiatric
diseases or less classical as the use of crayfish to study
the neurobiological bases of anxiety as underlined by
Pascal Fossat (Universite´ de Bordeaux) (Fossat et al.,
2014).
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